Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma
Bruce M. Elliott(St George's, University of London), Alan Spatz(Jewish General Hospital), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Eric Angevin(Institut Gustave Roussy), John F. Thompson(Melanoma Institute Australia), Serge Lebecque(Université Claude Bernard Lyon 1), Alexander M.M. Eggermont(University Medical Center Utrecht), Ulrich Keilholz(German Cancer Research Center), Donata Rimoldi(Ludwig Cancer Research), E. Musat(European Organisation for Research and Treatment of Cancer), Stefan Suciu(St James's University Hospital), O. Gugerli(University of Lausanne), Richard A. Scolyer(The University of Sydney), Raghwa Sharma(Royal Prince Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Martin Cook(Royal Surrey NHS Foundation Trust), Rona M. MacKie(University of Glasgow), Danielle Líénard(University Hospital of Lausanne)
Cited by 70
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k